Remus Pharma Approves Main Board Migration, Dominican Subsidiary, and Director Appointment
Remus Pharmaceuticals Ltd 路 Outcome 路 02 Sept 2026, 11:59 pm
Remus Pharma Approves Main Board Migration, Dominican Subsidiary, and Director Appointment On 2nd Sep'26, Remus Pharmaceuticals approved its migration from the NSE Emerge platform to the NSE and BSE Main Boards, subject to shareholder and regulatory approvals. The Board also authorized incorporating a pharmaceutical distribution subsidiary in the Dominican Republic to support global expansion, with Remus acquiring a 51%+ stake via cash consideration. Furthermore, entrepreneur Ashutosh Valani was appointed as a Non-Executive Independent Director for a five-year term to strengthen corporate governance and strategic oversight.
Original exchange filing (PDF)
More announcements from Remus Pharmaceuticals Ltd
- Remus Pharmaceuticals Limited has informed the Exchange about Transcript 路 06 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Audio Recording 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Investor Presentation 路 04 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange regarding a media release dated November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Interim Dividend is 07-Nov-2026. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on November 03, 2026, declared Interim Dividend of Rs. 1.00 per equity share. 路 03 Nov 2026
- Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026 路 03 Nov 2026
- Remus Pharmaceuticals Limited has informed the Exchange about Schedule of meet 路 29 Oct 2026
